Skip to content
value.today

Satsuma Pharmaceuticals, Inc.

🇺🇸 San Francisco, California, USAPharmaceuticalsFounded 2016
Total raised
$12 M
1 round on record
Latest round
$12 M
Dec 2016
First round on record
Dec 2016
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Satsuma Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2016$12 MNo. 1$10 to $50 million

Satsuma Pharmaceuticals, Inc.: Raise no. 1, Dec 2016

Investors in this round

4 investors had bought by the notice of Feb 12, 2018: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Satsuma Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered; $0 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Kollins · Executive Officer, Director
  • Tadayoshi Iwashima · Executive Officer
  • Heath Lukatch · Director
  • Michael Riebe · Director
  • Rajeev Shah · Director
  • Thomas King · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Kollins, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Feb 12, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Satsuma Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2018).

    SEC Form D · Feb 2018

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2018

That is all the official record says: Satsuma Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Satsuma Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Hadley Harbor Master Investors (Cayman) II L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
TPG Group Holdings (SBS) Advisors, Inc.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 4 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Satsuma Pharmaceuticals, Inc.
NameRoleNamed in
John KollinsExecutive officerFeb 2018
Tadayoshi IwashimaExecutive officerFeb 2018
Heath LukatchDirectorFeb 2018
John KollinsDirectorFeb 2018
Michael RiebeDirectorFeb 2018
Rajeev ShahDirectorFeb 2018
Thomas KingDirectorFeb 2018